Sol-Gel Technologies Ltd. Logo

Sol-Gel Technologies Ltd.

Develops and commercializes topical dermatology drugs for acne, rosacea, and rare skin conditions.

SLGL | US

Overview

Corporate Details

ISIN(s):
IL0011417206
LEI:
Country:
United States of America
Address:
7 GOLDA MEIR ST., 7403648 NESS ZIONA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sol-Gel Technologies Ltd. is a dermatology company engaged in the identification, development, and commercialization of topical drug products. The company has developed FDA-approved treatments, including Twyneo® for acne vulgaris and Epsolay® for inflammatory lesions of rosacea. Its clinical-stage pipeline focuses on delivering innovative treatments for rare skin conditions, with a lead candidate, patidegib gel, designed to prevent new basal cell carcinoma lesions in patients with Gorlin syndrome. Sol-Gel aims to address unmet patient needs by developing novel formulations that surpass the current standard of care in medical dermatology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Sol-Gel Technologies Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sol-Gel Technologies Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Sol-Gel Technologies Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America AVBP
ARROWHEAD PHARMACEUTICALS, INC. Logo
Develops RNAi medicines to silence genes causing intractable cardiometabolic and pulmonary diseases.
United States of America ARWR
ARS Pharmaceuticals, Inc. Logo
Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.
United States of America SPRY
ARTELO BIOSCIENCES, INC. Logo
Develops lipid-signaling therapeutics for cancer, pain, anxiety, and depression.
United States of America ARTL
Artiva Biotherapeutics, Inc. Logo
Develops allogeneic, off-the-shelf NK cell therapies for cancer and autoimmune diseases.
United States of America ARTV
Ascelia Pharma Logo
Develops novel drugs for rare oncology, including an oral MRI contrast agent for cancer patients.
Sweden ACE
Ascendis Pharma A/S Logo
Biopharma using proprietary TransCon® tech to develop therapies for rare diseases & oncology.
United States of America ASND
ASCENTAGE PHARMA GROUP INTERNATIONAL Logo
Biopharma developing small-molecule drugs for cancer, HBV, and age-related diseases.
United States of America AAPG

Talk to a Data Expert

Have a question? We'll get back to you promptly.